Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris

Figures & data

Table 1. Baseline characteristics of the volunteers.

	Value
N	36
Sex, n (%)
Males	14 (38.9)
Females	22 (61.1)
Median age (range), years	34.5 (19–50)
Race, n (%)
White	36 (100.0)
Fitzpatrick skin type, n (%)
II	5 (13.9)
III	30 (83.3)
IV	1 (2.8)
Median BMI (range), kg/m^2	22.9 (16.2–34.5)

BMI: body mass index

Figure 1. Box plot of visually assessed skin blanching scores at 2 h after treatment application for 16 h.The box plot shows the median (horizontal lines), range (boxes), 1.5× interquartile range (whiskers) and mean (circles). BD: betamethasone dipropionate 0.05%; Cal/BD: calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g; CP: clobetasol propionate 0.05%; HB: hydrocortisone-17-butyrate 0.1%; MF: mometasone furoate 0.1%; vehicle, foam vehicle.

Table 2. Visually assessed skin blanching scores at 2 h after non-occlusive application of the treatments for 16 h^a (N = 36).

Treatment	Mean (SD)	Median (range)	p Value (versus Cal/BD foam)^b
Cal/BD cutaneous foam	1.93 (0.56)	2.00 (0.75–3.00)	–
CP cream (very potent)	3.09 (0.55)	3.00 (1.75–4.00)	<.001
BD ointment (potent)	1.85 (0.59)	1.75 (0.75–3.00)	.30
MF cream (potent)	2.11 (0.59)	2.00 (1.00–3.75)	.22
HB ointment (moderately potent)	1.40 (0.66)	1.25 (0.50–3.00)	<.001
Cutaneous foam vehicle	0.06 (0.13)	0 (0–0.50)	<.001

^a Higher scores indicate greater skin blanching (5).

^b Wilcoxon signed rank test for between-treatment differences.

BD: betamethasone dipropionate 0.05%; Cal/BD: calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g; CP: clobetasol propionate 0.05%; HB: hydrocortisone-17-butyrate 0.1%; MF: mometasone furoate 0.1%; SD: standard deviation

Table 3. Results of analysis of variance of visually assessed skin blanching scores (N = 36).

Treatment	Between-treatment difference (95% CI)^a	p Value (versus Cal/BD foam)
Cal/BD cutaneous foam	–	–
CP cream (very potent)	−1.16 (−1.37, −0.95)	<.0001
BD ointment (potent)	0.08 (−0.13, 0.29)	.44
MF cream (potent)	−0.18 (−0.39, 0.03)	.09
HB ointment (moderately potent)	0.53 (0.32, 0.75)	<.0001
Cutaneous foam vehicle	1.87 (1.66, 2.08)	<.0001

^a Cal/BD cutaneous foam − comparator treatment.

BD: betamethasone dipropionate 0.05%; Cal/BD: calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g; CI: confidence interval; CP: clobetasol propionate 0.05%; HB: hydrocortisone-17-butyrate 0.1%; MF: mometasone furoate 0.1%

McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608–610.

 Web of Science ®Google Scholar